Developer docs
API playgroundTry for free, no card

Search company profiles

Bactiguard

Full company profile

uuid0006d3x

Namestring
Bactiguard
Legal namestring
Bactiguard Holding AB (publ)
Websiteurl
bactiguard.com
Company typeenum
Public
Founded yearint
2005
Descriptiontext

Bactiguard is a Swedish medical technology company founded in 2005 and listed on Nasdaq Stockholm (BACTI-B) that develops and licenses a proprietary infection-prevention coating called Bactiguard Infection Protection (BIP). The BIP technology is an ultra-thin noble metal alloy coating applied to medical device surfaces; when the coated device contacts bodily fluids, the noble metals create a galvanic effect that reduces microbial adhesion and prevents biofilm formation without releasing active substances into the patient. The technology has been clinically validated in over 40 publications covering more than 100,000 patients, with documented reductions of 69% in catheter-associated urinary tract infections (CAUTI) and 53% in ventilator-associated pneumonia (VAP), and more than 200 million coated devices have been used globally with no reported adverse events tied to the coating.

The company's primary business model is B2B licensing: Bactiguard partners with leading global medical device companies such as Becton Dickinson (Foley catheters, expanded in May 2026) and Zimmer Biomet (ZNN Bactiguard trauma nail, restructured December 2025) under multi-year contracts that include application development fees, exclusivity payments, and ongoing royalties once partner products reach market. Bactiguard also sells a wound management portfolio directly via regional distributors, most notably HYDROCYN aqua (a hypochlorous acid-based solution and gel for chronic and acute wounds) and surgical sutures, with recent geographic expansion through CDSCO approval in India. The model generates revenue across development, exclusivity, and full-license phases, and is supplemented by direct wound-care product sales.

Bactiguard's headcount sits between 101 and 250 employees, with headquarters in Stockholm and operational offices in Tullinge, Sweden. The leadership team is led by CEO Christine Lind, with Stefan Grass as Chief Medical Officer and Deputy CEO and Patrick Bach as CFO. The company is covered by analysts at SEB, Carnegie, and Kepler Cheuvreux. Operating geographies span Europe, North America, Asia Pacific (including India, China, and Malaysia), the Middle East (UAE), and Latin America (Ecuador, Peru). Reported nine-month 2025 revenue of SEK 163.2 million is down 15.7% year-over-year, although EBITDA remains positive at SEK 19.1 million for the same period following the company's first EBITDA-profitable year in 2024.

Short descriptiontext

Bactiguard is a Swedish medical technology company that licenses its proprietary noble metal alloy coating (BIP) to global MedTech partners such as Becton Dickinson and Zimmer Biomet to prevent infections on catheters, endotracheal tubes, and implants, and also sells HYDROCYN aqua wound care products through regional distributors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersStockholm, Sweden
HQ citystring
Stockholm
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
infection prevention coating, medical device licensing, noble metal alloy coating, antimicrobial medical devices, wound care products
Industry1 code
PRIMARYIMALAIAA
Primary Pharmaceutical Packaging (Blister Packs, Bottles, Vials, Ampoules)
NAICS code1 code
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical Device Infection Prevention
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1License Partnerships - Application Development
TypeLicensing Royalties
Description

Revenues generated during close collaboration with partners' R&D teams to explore application of infection prevention technology to underlying medical devices. Development work is confidential to protect competitive advantages.

bactiguard.com
2License Partnerships - Exclusivity
TypeLicensing Royalties
Description

Revenue from granting exclusive rights to apply the coating technology to certain medical devices. Partners may not yet have products in market due to pending regulatory approvals.

bactiguard.com
3License Partnerships - Full License
TypeLicensing Royalties
Description

Variable remuneration (royalties) once license partners' products reach the market and are sold in specified regions or globally. This represents ongoing recurring revenue as products commercialize.

bactiguard.com
4Wound Management Products
TypeHardware Sales
Description

Direct sales of wound care products including HYDROCYN aqua (solution and gel) and surgical sutures through selected local distributors.

bactiguard.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
Pricing details1 tier
1B2B License Partnership Model
ModelOtherBilling cadenceMulti-year contract
Notes

License revenues have three components: coating and process development revenues, revenues for rights to use coating technology on medical devices within specific application and geographic areas, and royalties as variable remuneration when products reach market.

news.cision.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1BIP (Bactiguard Infection Protection)
Description

The company's proprietary noble metal alloy coating technology applied to medical devices to prevent microbial adhesion and biofilm formation

bactiguard.com
+1 more record
Core offering1 text field

Bactiguard develops and licenses its proprietary Bactiguard Infection Protection (BIP) technology—an ultra-thin noble metal alloy coating that prevents microbial adhesion and biofilm formation on medical devices through a galvanic effect—to global MedTech partners for integration into their branded devices including Foley catheters, central venous catheters, endotracheal tubes, and orthopedic trauma implants. The company also distributes a wound management portfolio (HYDROCYN aqua hypochlorous acid wound care products and surgical sutures) through regional distributors to healthcare providers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 69% reduction in catheter-associated urinary tract infections (CAUTI)
+3 more records
Product overview1 text field

Bactiguard operates a dual-product business model: (1) a license-focused platform offering its proprietary Bactiguard Infection Protection (BIP) technology—a noble metal alloy coating that prevents microbial adhesion and biofilm formation on medical devices—which is integrated into partner MedTech companies' products including Foley catheters (standard and silicone variants), Foley TempSensor, Central Venous Catheters, Endotracheal Tubes (standard and Evac variants), and ZNN trauma nails; and (2) a proprietary Wound Management portfolio comprising HYDROCYN aqua (hypochlorous acid-based wound care solution) and surgical sutures, distributed through local distributors.

Product and service10 records
1Bactiguard Infection Protection (BIP) Technology
CategoryCore Technology Platform
Description

Core proprietary technology consisting of an ultra-thin noble metal alloy coating that prevents microbial adhesion and biofilm formation on medical devices through a galvanic effect when in contact with fluids. Licensed to MedTech partners for integration into their branded devices.

2BIP Foley Catheter
CategoryMedical Device (Urology)
Description

Urinary catheter with Bactiguard's infection prevention coating, intended for patients catheterized longer than two days to reduce catheter-associated urinary tract infections (CAUTI). Demonstrated 69% reduction in CAUTI in clinical studies.

3BIP Foley Catheter – Silicone
CategoryMedical Device (Urology)
Description

Silicone-based version of the BIP Foley Catheter offering the same infection prevention properties with a different material composition for patients with specific material compatibility requirements.

4BIP Foley TempSensor
CategoryMedical Device (Intensive Care)
Description

Foley catheter with integrated temperature sensor for continuous patient temperature monitoring during intensive care, combined with Bactiguard's infection prevention coating.

5BIP Central Venous Catheter
CategoryMedical Device (Intensive Care)
Description

Central venous catheter with Bactiguard coating designed to reduce catheter-related bloodstream infections (CRBSI) in intensive care settings.

6BIP Endotracheal Tube
CategoryMedical Device (Intensive Care)
Description

Endotracheal tube with Bactiguard coating to reduce microbial adhesion and ventilator-associated pneumonia (VAP) risk in mechanically ventilated patients.

7BIP Endotracheal Tube Evac
CategoryMedical Device (Intensive Care)
Description

Advanced endotracheal tube combining subglottic secretion drainage with Bactiguard's infection prevention coating, demonstrated to reduce VAP by 53% in the VITAL study published in Annals of Intensive Care.

8ZNN Bactiguard
CategoryMedical Device (Implants)
Description

Trauma nail system with Bactiguard coating for orthopedic applications, commercialized through license partnership with Zimmer Biomet outside the US for fracture fixation with infection prevention.

9HYDROCYN aqua
CategoryWound Care Product
Description

Advanced wound care portfolio containing hypochlorous acid (HOCl) for wound cleansing, debridement, and irrigation of chronic and acute wounds, supporting healing and infection prevention. Available as solution and gel. Distributed through selected local distributors.

10Surgical Sutures
CategoryWound Care Product
Description

Range of surgical sutures offered as part of Bactiguard's wound management portfolio, sold through selected local distributors in various regions.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-06-23
Description

Global licensing partnership for infection-prevention catheter technologies. Becton Dickinson licenses Bactiguard's coating technology for application to Foley catheters and other infection prevention products sold globally under the BD brand. The partnership was strengthened in 2026 to expand access to Foley catheters designed to reduce infection risk for patients worldwide.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-12-19
Description

Updated trauma license agreement for commercialization of ZNN Bactiguard coated trauma nail system outside the US. The revised deal gives Zimmer Biomet non-exclusive rights in specific regions, with Bactiguard regaining global rights and receiving royalties and fixed fees.

3European Bone and Joint Infection Society (EBJIS)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-03-16
Description

Bactiguard joined Zimmer Biomet at EBJIS conference in Barcelona to showcase the ZNN Bactiguard technology and demonstrate how the infection prevention coating works in orthopedic applications.

bactiguard.com
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Collaboration on HAI Proactive project funded by Swedish Innovation Agency Vinnova, focused on reducing healthcare-associated infections through new technology. Project stakeholders include Karolinska University Hospital, Umeå University Hospital, Region Stockholm, Region Västernorrland, and Bactiguard.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Annual Global Wound Management Webinar collaboration with King's College Hospital London on wound care best practices and Hydrocyn Aqua product education, with over 300 participants from Europe and Asia.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Privately held MedTech with ostomy, continence, and wound care products; comparable in wound care and continence categories where Bactiguard's catheter and HYDROCYN offerings compete.

TypeBroad incumbent
Description

Diversified MedTech with substantial wound management franchise (Allevyn, PICO) and orthopedics; an established incumbent overlapping Bactiguard's wound care and orthopedic coating markets.

TypeDirect peer
Description

Specialist antimicrobial coating company developing infection-prevention technologies for medical devices and wound care, overlapping with Bactiguard's BIP coating and HYDROCYN wound care platforms.

TypeDirect peer
Description

Provider of silver-based antimicrobial technologies licensed into medical devices and consumer products; competes with Bactiguard for MedTech license partnerships in catheter and device coating applications.

TypeOthers
Description

Bactiguard's largest license partner for Foley catheters; while not a competitor in the coating technology itself, BD's own coating R&D and pricing decisions materially affect Bactiguard's royalty trajectory.

TypeBroad incumbent
Description

Global leader in ostomy, continence, and wound care, with significant catheter business; competes broadly with Bactiguard's urology catheter license partners and overlaps in advanced wound care.

TypeOthers
Description

Supplier of biocompatible coatings and materials used on medical devices; adjacent enabling technology provider with overlapping customer base of catheter and implant manufacturers.

TypeBroad incumbent
Description

Private global MedTech focused on wound care (Mepilex, Avance) and surgical solutions; comparable wound management competitor with stronger direct commercial reach than Bactiguard.

TypeBroad incumbent
Description

Large medical products company with wound care, ostomy, and continence portfolios; competes with Bactiguard's HYDROCYN aqua wound management products across hospital and homecare channels.

TypeDirect peer
Description

Global MedTech company with a portfolio of coated urinary catheters and endotracheal tubes (including Arrow and Rusch brands); competes directly with Bactiguard's licensed catheter franchise via silver and antimicrobial-coated offerings.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bactiguard

Medical Device Infection Preventionbactiguard.com

Bactiguard is a Swedish medical technology company that licenses its proprietary noble metal alloy coating (BIP) to global MedTech partners such as Becton Dickinson and Zimmer Biomet to prevent infections on catheters, endotracheal tubes, and implants, and also sells HYDROCYN aqua wound care products through regional distributors.

What Bactiguard does

Bactiguard is a Swedish medical technology company founded in 2005 and listed on Nasdaq Stockholm (BACTI-B) that develops and licenses a proprietary infection-prevention coating called Bactiguard Infection Protection (BIP). The BIP technology is an ultra-thin noble metal alloy coating applied to medical device surfaces; when the coated device contacts bodily fluids, the noble metals create a galvanic effect that reduces microbial adhesion and prevents biofilm formation without releasing active substances into the patient. The technology has been clinically validated in over 40 publications covering more than 100,000 patients, with documented reductions of 69% in catheter-associated urinary tract infections (CAUTI) and 53% in ventilator-associated pneumonia (VAP), and more than 200 million coated devices have been used globally with no reported adverse events tied to the coating.

The company's primary business model is B2B licensing: Bactiguard partners with leading global medical device companies such as Becton Dickinson (Foley catheters, expanded in May 2026) and Zimmer Biomet (ZNN Bactiguard trauma nail, restructured December 2025) under multi-year contracts that include application development fees, exclusivity payments, and ongoing royalties once partner products reach market. Bactiguard also sells a wound management portfolio directly via regional distributors, most notably HYDROCYN aqua (a hypochlorous acid-based solution and gel for chronic and acute wounds) and surgical sutures, with recent geographic expansion through CDSCO approval in India. The model generates revenue across development, exclusivity, and full-license phases, and is supplemented by direct wound-care product sales.

Bactiguard's headcount sits between 101 and 250 employees, with headquarters in Stockholm and operational offices in Tullinge, Sweden. The leadership team is led by CEO Christine Lind, with Stefan Grass as Chief Medical Officer and Deputy CEO and Patrick Bach as CFO. The company is covered by analysts at SEB, Carnegie, and Kepler Cheuvreux. Operating geographies span Europe, North America, Asia Pacific (including India, China, and Malaysia), the Middle East (UAE), and Latin America (Ecuador, Peru). Reported nine-month 2025 revenue of SEK 163.2 million is down 15.7% year-over-year, although EBITDA remains positive at SEK 19.1 million for the same period following the company's first EBITDA-profitable year in 2024.

Bactiguard firmographics

Firmographics
Name
Bactiguard
Legal name
Bactiguard Holding AB (publ)
Website
https://bactiguard.com
Company type
Public
Founded year
2005
Operating status
Operating
Headcount range
51–100 employees
Short description
Bactiguard is a Swedish medical technology company that licenses its proprietary noble metal alloy coating (BIP) to global MedTech partners such as Becton Dickinson and Zimmer Biomet to prevent infections on catheters, endotracheal tubes, and implants, and also sells HYDROCYN aqua wound care products through regional distributors.
Ownership category
akta.pro rank

Bactiguard industry classification

Industry
Product category
Medical Device Infection Prevention
NAICS
Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYIMALAIAA
Primary Pharmaceutical Packaging (Blister Packs, Bottles, Vials, Ampoules)

Keywords

  • Infection prevention coating
  • Medical device licensing
  • Noble metal alloy coating
  • Antimicrobial medical devices
  • Wound care products

Where Bactiguard is headquartered

Location

Headquarters

HQ city
Stockholm
HQ country
Sweden
HQ region
Europe

Offices2 records

Markets served

Bactiguard business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

  1. License Partnerships - Application Development: Revenues generated during close collaboration with partners' R&D teams to explore application of infection prevention technology to underlying medical devices. Development work is confidential to protect competitive advantages.
  2. License Partnerships - Exclusivity: Revenue from granting exclusive rights to apply the coating technology to certain medical devices. Partners may not yet have products in market due to pending regulatory approvals.
  3. License Partnerships - Full License: Variable remuneration (royalties) once license partners' products reach the market and are sold in specified regions or globally. This represents ongoing recurring revenue as products commercialize.
  4. Wound Management Products: Direct sales of wound care products including HYDROCYN aqua (solution and gel) and surgical sutures through selected local distributors.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractB2B License Partnership Model

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Bactiguard product offering

Product offering

Core offering

Bactiguard develops and licenses its proprietary Bactiguard Infection Protection (BIP) technology—an ultra-thin noble metal alloy coating that prevents microbial adhesion and biofilm formation on medical devices through a galvanic effect—to global MedTech partners for integration into their branded devices including Foley catheters, central venous catheters, endotracheal tubes, and orthopedic trauma implants. The company also distributes a wound management portfolio (HYDROCYN aqua hypochlorous acid wound care products and surgical sutures) through regional distributors to healthcare providers.

Product overview

Bactiguard operates a dual-product business model: (1) a license-focused platform offering its proprietary Bactiguard Infection Protection (BIP) technology—a noble metal alloy coating that prevents microbial adhesion and biofilm formation on medical devices—which is integrated into partner MedTech companies' products including Foley catheters (standard and silicone variants), Foley TempSensor, Central Venous Catheters, Endotracheal Tubes (standard and Evac variants), and ZNN trauma nails; and (2) a proprietary Wound Management portfolio comprising HYDROCYN aqua (hypochlorous acid-based wound care solution) and surgical sutures, distributed through local distributors.

Differentiator

Problem solved

Functional benefit

Brands

  • BIP (Bactiguard Infection Protection): The company's proprietary noble metal alloy coating technology applied to medical devices to prevent microbial adhesion and biofilm formation
  • HYDROCYN aqua

Products and services

  • Bactiguard Infection Protection (BIP) Technology Core proprietary technology consisting of an ultra-thin noble metal alloy coating that prevents microbial adhesion and biofilm formation on medical devices through a galvanic effect when in contact with fluids. Licensed to MedTech partners for integration into their branded devices.
  • BIP Foley Catheter Urinary catheter with Bactiguard's infection prevention coating, intended for patients catheterized longer than two days to reduce catheter-associated urinary tract infections (CAUTI). Demonstrated 69% reduction in CAUTI in clinical studies.
  • BIP Foley Catheter – Silicone Silicone-based version of the BIP Foley Catheter offering the same infection prevention properties with a different material composition for patients with specific material compatibility requirements.
  • BIP Foley TempSensor Foley catheter with integrated temperature sensor for continuous patient temperature monitoring during intensive care, combined with Bactiguard's infection prevention coating.
  • BIP Central Venous Catheter Central venous catheter with Bactiguard coating designed to reduce catheter-related bloodstream infections (CRBSI) in intensive care settings.
  • BIP Endotracheal Tube Endotracheal tube with Bactiguard coating to reduce microbial adhesion and ventilator-associated pneumonia (VAP) risk in mechanically ventilated patients.
  • BIP Endotracheal Tube Evac Advanced endotracheal tube combining subglottic secretion drainage with Bactiguard's infection prevention coating, demonstrated to reduce VAP by 53% in the VITAL study published in Annals of Intensive Care.
  • ZNN Bactiguard Trauma nail system with Bactiguard coating for orthopedic applications, commercialized through license partnership with Zimmer Biomet outside the US for fracture fixation with infection prevention.
  • HYDROCYN aqua Advanced wound care portfolio containing hypochlorous acid (HOCl) for wound cleansing, debridement, and irrigation of chronic and acute wounds, supporting healing and infection prevention. Available as solution and gel. Distributed through selected local distributors.
  • Surgical Sutures Range of surgical sutures offered as part of Bactiguard's wound management portfolio, sold through selected local distributors in various regions.

Quantifiable outcome

  • 69% reduction in catheter-associated urinary tract infections (CAUTI)
  • +3 more outcomes

Companies that use Bactiguard

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Bactiguard technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Bactiguard partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core, minor and strategic.

  • Becton DickinsoncoreOEM/ Whitelabel/ Licensing Partner · 23 June 2026Global licensing partnership for infection-prevention catheter technologies. Becton Dickinson licenses Bactiguard's coating technology for application to Foley catheters and other infection prevention products sold globally under the BD brand. The partnership was strengthened in 2026 to expand access to Foley catheters designed to reduce infection risk for patients worldwide.
  • Zimmer BiometcoreOEM/ Whitelabel/ Licensing Partner · 19 December 2025Updated trauma license agreement for commercialization of ZNN Bactiguard coated trauma nail system outside the US. The revised deal gives Zimmer Biomet non-exclusive rights in specific regions, with Bactiguard regaining global rights and receiving royalties and fixed fees.
  • European Bone and Joint Infection Society (EBJIS)minorStrategic or Co-development Partner · 16 March 2025Bactiguard joined Zimmer Biomet at EBJIS conference in Barcelona to showcase the ZNN Bactiguard technology and demonstrate how the infection prevention coating works in orthopedic applications.
  • Karolinska Institute and Umeå UniversitystrategicStrategic or Co-development PartnerCollaboration on HAI Proactive project funded by Swedish Innovation Agency Vinnova, focused on reducing healthcare-associated infections through new technology. Project stakeholders include Karolinska University Hospital, Umeå University Hospital, Region Stockholm, Region Västernorrland, and Bactiguard.
  • King's College Hospital LondonstrategicStrategic or Co-development PartnerAnnual Global Wound Management Webinar collaboration with King's College Hospital London on wound care best practices and Hydrocyn Aqua product education, with over 300 participants from Europe and Asia.

Scale indicators13 records

Recent moves9 records

Expansion highlights6 records

Bactiguard competitors and assessment

Company assessment

Broad incumbents

  • Hollister Incorporated: Privately held MedTech with ostomy, continence, and wound care products; comparable in wound care and continence categories where Bactiguard's catheter and HYDROCYN offerings compete.
  • Smith+Nephew: Diversified MedTech with substantial wound management franchise (Allevyn, PICO) and orthopedics; an established incumbent overlapping Bactiguard's wound care and orthopedic coating markets.
  • Coloplast: Global leader in ostomy, continence, and wound care, with significant catheter business; competes broadly with Bactiguard's urology catheter license partners and overlaps in advanced wound care.
  • Mölnlycke Health Care: Private global MedTech focused on wound care (Mepilex, Avance) and surgical solutions; comparable wound management competitor with stronger direct commercial reach than Bactiguard.
  • Convatec: Large medical products company with wound care, ostomy, and continence portfolios; competes with Bactiguard's HYDROCYN aqua wound management products across hospital and homecare channels.

Direct peers

  • Covalon Technologies: Specialist antimicrobial coating company developing infection-prevention technologies for medical devices and wound care, overlapping with Bactiguard's BIP coating and HYDROCYN wound care platforms.
  • Sciessent (formerly Agion): Provider of silver-based antimicrobial technologies licensed into medical devices and consumer products; competes with Bactiguard for MedTech license partnerships in catheter and device coating applications.
  • Teleflex: Global MedTech company with a portfolio of coated urinary catheters and endotracheal tubes (including Arrow and Rusch brands); competes directly with Bactiguard's licensed catheter franchise via silver and antimicrobial-coated offerings.

Others

  • Becton Dickinson (BD): Bactiguard's largest license partner for Foley catheters; while not a competitor in the coating technology itself, BD's own coating R&D and pricing decisions materially affect Bactiguard's royalty trajectory.
  • DSM Biomedical (Royal DSM): Supplier of biocompatible coatings and materials used on medical devices; adjacent enabling technology provider with overlapping customer base of catheter and implant manufacturers.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Bactiguard social profiles

Digital presence

Bactiguard financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bactiguard leadership team

Management profile

Number of profiles

Profiles8 records

Bactiguard funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bactiguard M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bactiguard

What does Bactiguard do?

Bactiguard develops and licenses its proprietary Bactiguard Infection Protection (BIP) technology—an ultra-thin noble metal alloy coating that prevents microbial adhesion and biofilm formation on medical devices through a galvanic effect—to global MedTech partners for integration into their branded devices including Foley catheters, central venous catheters, endotracheal tubes, and orthopedic trauma implants. The company also distributes a wound management portfolio (HYDROCYN aqua hypochlorous acid wound care products and surgical sutures) through regional distributors to healthcare providers.

Is Bactiguard a public or private company?

Bactiguard is a public company. It is classified as public and is currently operating.

When was Bactiguard founded?

Bactiguard was founded in 2005. It employs 51 to 100 people.

Where is Bactiguard based?

Bactiguard is headquartered in Stockholm, Sweden, in the Europe region.

How does Bactiguard make money?

Four revenue lines are on record. License Partnerships - Application Development is the primary driver. The others are license Partnerships - Exclusivity, license Partnerships - Full License and wound Management Products.

Who are Bactiguard's main competitors?

Broad incumbents on record are Hollister Incorporated, Smith+Nephew, Coloplast, Mölnlycke Health Care and Convatec. Direct peers are Covalon Technologies, Sciessent (formerly Agion) and Teleflex. Others are Becton Dickinson (BD) and DSM Biomedical (Royal DSM).

Does Bactiguard have an API?

No public API is recorded for Bactiguard.

What industry is Bactiguard in?

Bactiguard's product category is Medical Device Infection Prevention. Its primary akta.pro industry code is IMALAIAA, Primary Pharmaceutical Packaging (Blister Packs, Bottles, Vials, Ampoules). Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comBactiguard Q3 2026 slides: EBITDA soars on license growthBactiguard reported Q3 2026 results on October 22, with adjusted EBITDA more than tripling to SEK 20 million on a 34% margin. License revenue surged 40% to SEK 41.9 million, and operating cash flow turned positive at SEK 14 million. The company reiterated 2030 targets of over SEK 600 million in revenue and SEK 200 million in EBITDA.TradingViewBactiguard Q3 2026 Earnings Call Is LiveBactiguard's Q3 2026 earnings call is live, with executives discussing financial results and answering analyst questions. The call may include surprise news, and management commentary on demand, margins, or capital spending could move markets.Dagens industriGrundaren säljer allt i Bactiguard – till jättepremieChristian Kinch, founder and former CEO of Bactiguard, is selling his entire stake to Tombact AB, controlled by the company's largest shareholder Thomas von Koch, in a deal described as a significant premium. The article is behind a paywall, so the exact valuation was not disclosed.Dagens industriHögre omsättning men sämre resultat för BactiguardMedical technology company Bactiguard reported Q2 2026 results showing higher turnover but a worse bottom line, with a net loss after tax of 8.2 million SEK compared to 8.1 million SEK loss in the corresponding period of the previous year. The quarterly report was published on July 14, 2026.Dagens industriMedicinteknikbolaget gör nyemissionMedical technology company Bactiguard has announced a decision to conduct a directed new issue of redemption and convertible C-shares, alongside a share repurchase program for C-series shares. The announcement was made on July 8, 2026, though the article provides limited details on the size or terms of the issuance. This represents a capital structuring move by the company to raise funds or optimize its share capital structure.GlobeNewswireFoley Catheters Market Size Expected to Reach USD 1.21 Billion by 2030 | MarketsandMarkets™The global Foley catheters market is projected to grow from USD 0.93 billion in 2025 to USD 1.20 billion by 2030 at a CAGR of 5.3%, driven by increasing prevalence of urological disorders, aging populations, and expanding healthcare access in emerging economies. The Asia Pacific region is expected to record the highest growth rate, while manufacturers are advancing catheter technologies through antimicrobial coatings, silicone-based materials, and infection-prevention innovations to address catheter-associated urinary tract infections. Recent industry developments include Amsino International's launch of AMSure Foley Catheter Trays in 2025, Medline's home-delivery partnership with TenderHeart Health Outcomes, and Becton Dickinson's global licensing partnership with Bactiguard for infection-prevention catheter technologies.news.cision.comBactiguard announces updated trauma license agreement with Zimmer BiometBactiguard announced an updated trauma license agreement with Zimmer Biomet, granting the latter non-exclusive rights to commercialize the ZNN Bactiguard coated trauma nail system across European markets, selected MEA markets, and Japan, while Bactiguard regains its remaining global rights within trauma. The new agreement replaces annual minimum royalties with quarterly fixed fees representing no less than half of the previous minimum royalty amount annually, with no negative financial impact for 2025 and no change to Bactiguard's 2030 strategic and financial targets.news.cision.comNomination Committee appointed for Bactiguard Holding AB’s Annual General Meeting 2026The Nomination Committee for Bactiguard Holding AB's Annual General Meeting 2026 has been appointed, consisting of five members representing the company's largest shareholders. The committee, which includes representatives from TomBact AB, GIDL Invest AB, Nordea Fonder, and Fjärde AP Fonden, will propose board elections, auditor appointments, and related remuneration. Shareholders may submit proposals to the committee until January 15, 2026.